598 related articles for article (PubMed ID: 17923351)
1. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
[TBL] [Abstract][Full Text] [Related]
2. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
[TBL] [Abstract][Full Text] [Related]
3. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
4. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
5. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
6. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
[TBL] [Abstract][Full Text] [Related]
7. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study.
Greenberg B; Thomas I; Banish D; Goldman S; Havranek E; Massie BM; Zhu Y; Ticho B; Abraham WT
J Am Coll Cardiol; 2007 Aug; 50(7):600-6. PubMed ID: 17692744
[TBL] [Abstract][Full Text] [Related]
8. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
Voors AA; Dittrich HC; Massie BM; DeLucca P; Mansoor GA; Metra M; Cotter G; Weatherley BD; Ponikowski P; Teerlink JR; Cleland JG; O'Connor CM; Givertz MM
J Am Coll Cardiol; 2011 May; 57(19):1899-907. PubMed ID: 21545947
[TBL] [Abstract][Full Text] [Related]
9. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Chen HH; Redfield MM; Nordstrom LJ; Cataliotti A; Burnett JC
Am J Physiol Renal Physiol; 2003 May; 284(5):F1115-9. PubMed ID: 12676739
[TBL] [Abstract][Full Text] [Related]
11. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure.
Rogers HL; Marshall J; Bock J; Dowling TC; Feller E; Robinson S; Gottlieb SS
J Card Fail; 2008 Feb; 14(1):1-5. PubMed ID: 18226766
[TBL] [Abstract][Full Text] [Related]
13. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[TBL] [Abstract][Full Text] [Related]
14. Functional role of endogenous adenosine in human chronic renal disease.
Balakrishnan VS; Coles GA; Williams JD
Exp Nephrol; 1996; 4(1):26-36. PubMed ID: 8788597
[TBL] [Abstract][Full Text] [Related]
15. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
Paulsen L; Holm C; Bech JN; Starklint J; Pedersen EB
Nephrol Dial Transplant; 2008 May; 23(5):1556-61. PubMed ID: 18065809
[TBL] [Abstract][Full Text] [Related]
16. Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2 diabetes.
Farker K; Merkel U; Schweer H; Haerting J; Madani SF; Eggers R; Müller UA; Seyberth HW; Hoffmann A
Eur J Clin Pharmacol; 2002 May; 58(2):85-91. PubMed ID: 12012138
[TBL] [Abstract][Full Text] [Related]
17. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study.
Chen HH; Sundt TM; Cook DJ; Heublein DM; Burnett JC
Circulation; 2007 Sep; 116(11 Suppl):I134-8. PubMed ID: 17846293
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
20. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
